Literature DB >> 20373908

Mode of breathing-tidal or slow and deep-through the I-neb Adaptive Aerosol Delivery (AAD) system affects lung deposition of (99m)Tc-DTPA.

Kurt Nikander1, Ivan Prince, Steven Coughlin, Simon Warren, Glyn Taylor.   

Abstract

BACKGROUND: The I-neb AAD System was designed to deliver aerosol with two different breathing pattern algorithms: the Tidal Breathing Mode (TBM) and the Target Inhalation Mode (TIM). For the purpose of the study, the TBM breathing pattern algorithm was set to guide the subjects to inhalation during tidal breathing with aerosol pulsed during 50-80% of the time spent on inhalation, whereas the TIM breathing pattern was set to guide the subject to a slow and deep inhalation of up to approximately 9 sec with aerosol pulsed for up to 7 sec, leaving 2 sec for particle deposition in the lungs. In TIM, the inspiratory flow was guided to approximately 20 L/min through a built-in resistance in the mouthpiece.
METHODS: We have, in a randomized, open-label, crossover study of 12 healthy subjects evaluated lung deposition following administration of a radiolabeled aerosol from the I-neb AAD System with the TBM and TIM breathing patterns.
RESULTS: The results showed that mean lung deposition was significantly higher when using the I-neb AAD System with the TIM breathing pattern (73.3%) than with the TBM breathing pattern (62.8%). The mean exhaled fractions were low (<1%) for both breathing patterns. The nebulization time was significantly shorter with the TIM breathing pattern (3.0 min) than with the TBM breathing pattern (4.7 min).
CONCLUSIONS: The results of the present study showed that lung deposition with the slow and deep inhalation achieved through the I-neb AAD System in TIM was superior to the lung deposition achieved during tidal breathing in TBM. With the combination of high lung deposition, almost no loss of aerosol during exhalation, and short nebulization time the I-neb AAD System with the TIM breathing pattern should be of special value to patients who require multiple daily dosing of aerosolized medication, are using drugs that should not be wasted into the room air, or would benefit from a more efficient delivery system.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20373908      PMCID: PMC3116638          DOI: 10.1089/jamp.2009.0786

Source DB:  PubMed          Journal:  J Aerosol Med Pulm Drug Deliv        ISSN: 1941-2711            Impact factor:   2.849


  9 in total

1.  Adaptive Aerosol Delivery (AAD) technology.

Authors:  J Denyer; K Nikander; N J Smith
Journal:  Expert Opin Drug Deliv       Date:  2004-11       Impact factor: 6.648

2.  History of aerosol therapy: liquid nebulization to MDIs to DPIs.

Authors:  Paula J Anderson
Journal:  Respir Care       Date:  2005-09       Impact factor: 2.258

3.  Human variation in the peripheral air-space deposition of inhaled particles.

Authors:  W D Bennett; G C Smaldone
Journal:  J Appl Physiol (1985)       Date:  1987-04

4.  Evaluation of the Target Inhalation Mode (TIM) breathing maneuver in simulated nebulizer therapy in patients with cystic fibrosis.

Authors:  John Denyer; Ivan Prince; Emma Dixon; Penny Agent; Jennifer Pryor; Margaret Hodson
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

5.  Delivery of iloprost inhalation solution with the HaloLite, Prodose, and I-neb Adaptive Aerosol Delivery systems: an in vitro study.

Authors:  Robert E Van Dyke; Kurt Nikander
Journal:  Respir Care       Date:  2007-02       Impact factor: 2.258

6.  Human tracheobronchial deposition and effect of a cholinergic aerosol inhaled by extremely slow inhalations.

Authors:  M Anderson; M Svartengren; P Camner
Journal:  Exp Lung Res       Date:  1999-06       Impact factor: 2.459

7.  Systemic availability and lung deposition of budesonide via three different nebulizers in adults.

Authors:  Kerstin Dahlström; Lars Thorsson; Per Larsson; Kurt Nikander
Journal:  Ann Allergy Asthma Immunol       Date:  2003-02       Impact factor: 6.347

8.  Effects of various inhalation modes on the deposition of radioactive pressurized aerosols.

Authors:  S P Newman; D Pavia; N Garland; S W Clarke
Journal:  Eur J Respir Dis Suppl       Date:  1982

9.  Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency.

Authors:  P Brand; M Schulte; M Wencker; C H Herpich; G Klein; K Hanna; T Meyer
Journal:  Eur Respir J       Date:  2009-02-27       Impact factor: 16.671

  9 in total
  25 in total

1.  Intelligent nebulizers in the age of the Internet: The I-neb Adaptive Aerosol Delivery (AAD) system.

Authors:  Rajiv Dhand
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

2.  A novel micropump droplet generator for aerosol drug delivery: Design simulations.

Authors:  Guoguang Su; P Worth Longest; Ramana M Pidaparti
Journal:  Biomicrofluidics       Date:  2010-11-19       Impact factor: 2.800

Review 3.  Devices for Improved Delivery of Nebulized Pharmaceutical Aerosols to the Lungs.

Authors:  Worth Longest; Benjamin Spence; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2019-07-09       Impact factor: 2.849

4.  SPECT-CT Comparison of Lung Deposition using a System combining a Vibrating-mesh Nebulizer with a Valved Holding Chamber and a Conventional Jet Nebulizer: a Randomized Cross-over Study.

Authors:  Jonathan Dugernier; Michel Hesse; Rita Vanbever; Virginie Depoortere; Jean Roeseler; Jean-Bernard Michotte; Pierre-François Laterre; François Jamar; Gregory Reychler
Journal:  Pharm Res       Date:  2016-11-07       Impact factor: 4.200

5.  High-efficiency generation and delivery of aerosols through nasal cannula during noninvasive ventilation.

Authors:  P Worth Longest; Ross L Walenga; Yoen-Ju Son; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2012-12-28       Impact factor: 2.849

6.  Targeting aerosol deposition to and within the lung airways using excipient enhanced growth.

Authors:  Geng Tian; P Worth Longest; Xiang Li; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2013-01-03       Impact factor: 2.849

7.  Regional Ventilation Is the Main Determinant of Alveolar Deposition of Coarse Particles in the Supine Healthy Human Lung During Tidal Breathing.

Authors:  Rui Carlos Sá; Kirby L Zeman; William D Bennett; G Kim Prisk; Chantal Darquenne
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2017-03-09       Impact factor: 2.849

Review 8.  Advances in device and formulation technologies for pulmonary drug delivery.

Authors:  John Gar Yan Chan; Jennifer Wong; Qi Tony Zhou; Sharon Shui Yee Leung; Hak-Kim Chan
Journal:  AAPS PharmSciTech       Date:  2014-04-12       Impact factor: 3.246

9.  Production of Inhalable Submicrometer Aerosols from Conventional Mesh Nebulizers for Improved Respiratory Drug Delivery.

Authors:  P Worth Longest; Benjamin M Spence; Landon T Holbrook; Karla M Mossi; Yoen-Ju Son; Michael Hindle
Journal:  J Aerosol Sci       Date:  2012-04-14       Impact factor: 3.433

10.  The I-neb Adaptive Aerosol Delivery System enhances delivery of alpha1-antitrypsin with controlled inhalation.

Authors:  David E Geller; Kenneth C Kesser
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.